International experience with performance-based risk-sharing arrangements: implications for the Chinese innovative pharmaceutical market

Abstract

Objectives Various forms of outcomes-based or risk-sharing agreements have been implemented since early 2000s as a way of access to innovative medicinal products. This study aims to summarize the international experience of performance-based risk-sharing arrangements (PBRSAs) and identify the preconditions for a successful implementation of such schemes. Their implications for the Chinese healthcare market are discussed. Methods A systematic literature review (in PubMed) was conducted to review the evidence on the nature and performance of PBRSAs in the past 10 years. Grey literature was searched for reports in government websites of the countries in scope. Results The search identifies 463 records from PubMed and 3 additional records from other sources. Thirty-one publications are included in the final review. The following preconditions were identified to support a successful implementation of PBRSAs: (1) Identify meaningful and feasible outcome measurements; (2) Establish an effective and efficient data collection infrastructure; (3) Control of the implementation costs; (4) Develop governance and administrative infrastructure to allow delisting and rebate/refund; (5) Clarify personal data protection issues. Conclusions The implementation of PBRSAs has proven to be challenging. Although the Chinese healthcare system is not yet well equipped to implement such schemes, some recent changes may pave the way to successful PBRSAs for particular innovative products.

Procurement of medicines to treat cancer, 2015–2020, China

“…Although China has registries and databases for patient-level and drug utilization data, the patient-level data are limited, and the quality of the data is insufficient to support risk-sharing arrangements. 35 However, with the implementation of the diagnosis-related groups system (a system that groups patients with similar diagnoses who require similar hospital services), which is being piloted in China, and further investment in medical databases, risk-sharing arrangements are possible strategy choices for Chinese policy-makers in future.…”

Venture Risk of Small- and Medium-Sized Sci-Tech Enterprises Based on Markov Model

“…The ownership of independent intellectual property rights is not only related to the development fate of enterprises but also related to the innovation ability of industries, regions, and countries and the ability of core competition [7]. In various industries and various enterprises, technology-based SMEs have relatively high innovation efficiency and relatively low trial and error costs, which are the foundation of national innovation [8]. In recent years, these risk problems have aroused the general concern and attention of governments, business circles, and academic circles in various countries.…”